Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii
Journal of Infection, Volume 53, No. 4, Year 2006
Notification
URL copied to clipboard!
Description
Introduction: The increased incidence of nosocomial infections by multi-drug resistant Acinetobacter baumannii creates demand on the application of some combinations of older antimicrobials on that species. We conducted the present observational study to evaluate the efficacy of intravenous and aerosolized colistin combined with rifampicin in the treatment of critically patients with nosocomial infections caused by multiresistant A. baumannii. Patients and methods: Critically ill patients with nosocomial infections caused by A. baumannii resistant to all antibiotics except colistin in a medical intensive care unit. Diagnosis of infection was based on clinical data and isolation of bacteria. The bacterial susceptibilities to colistin were tested. Clinical response to colistin + rifampicin was evaluated. Results: Twenty-six patients (43.58 ± 18.29 years, Acute Physiology and Chronic Health Evaluation II Score (APACHE II): 6.35 ± 2.99), of whom 16 cases of nosocomial pneumonia treated by aerosolized colistin (1 × 106 IU three times/day) associated with intravenous rifampicin (10 mg/kg every 12 h), nine cases of bacteraemia treated by intravenous colistin (2 × 106 IU three times/day) associated with intravenous rifampicin (10 mg/kg every 12 h) in which three cases associated with ventilator associated pneumonia and one case of nosocomial meningitis treated by intrathecal use of colistin associated with intravenous rifampicin. The clinical evolution was favourable for all ill patients. Concerning side effects, we have noticed a moderate hepatic cytolysis in three patients. Conclusion: This is the first clinical report of colistin combined with rifampicin for treatment of A. baumannii infection. Despite the lack of a control group and the limited number of patients, the results seem to be encouraging. © 2005 The British Infection Society.
Authors & Co-Authors
Motaouakkil, Said
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Charra, Boubaker
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Hachimi, A.
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Nejmi, Hicham
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Benslama, Abdellatif
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
El Mdaghri, Naima
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Belabbès, Houria
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Benbachir, Mohamed
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Statistics
Citations: 166
Authors: 8
Affiliations: 1
Identifiers
Doi:
10.1016/j.jinf.2005.11.019
ISSN:
01634453
Study Design
Randomised Control Trial
Cohort Study